Clinical Trial Update: QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial update for QR12000 compound tablets in patients with essential hypertension; the study is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• QR12000 compound tablets (QR12000)

Snippet

Sponsor: Wuhan Createrna Science and Technology Co., Ltd | Conditions: Essential Hypertension | Phase 3 | Status: NOT_YET_RECRUITING